Elanco Animal Health NYSE: ELAN President and CEO Jeff Simmons outlined the company's growth strategy, product launches, deleveraging plans and outlook for its pet health and farm animal businesses during the Bank of America Healthcare Conference in London.
Elanco Animal Health Incorporated (ELAN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
I recommend a buy rating for Elanco Animal Health, driven by a strong new product cycle and robust clinic adoption. Zenrelia and Credelio Quattro are gaining significant market share, supporting double-digit revenue growth and margin expansion for ELAN. Befrena offers another growth lever, with early demand exceeding expectations, though near-term contribution is limited by supply constraints.
| Specialty Retail Industry | Consumer Discretionary Sector | Jeffrey N. Simmons CEO | XSTU Exchange | 28414H103 CUSIP |
| US Country | 9,650 Employees | - Last Dividend | - Last Split | - IPO Date |
Elanco Animal Health Incorporated is an animal health company founded in 1954 with its headquarters in Greenfield, Indiana. Specializing in the innovation, development, manufacturing, and marketing of products for pets and farm animals, Elanco aims to improve the health and productivity of those animals through a comprehensive range of products. The company distributes its offerings globally, catering to third-party distributors, veterinarians, and farm animal producers, which include beef and dairy farmers, as well as those involved in pork, poultry, and aquaculture operations.